Does the media refer more to NKTR or CYTK?

In the previous week, Cytokinetics had 24 more articles in the media than Nektar Therapeutics. MarketBeat recorded 25 mentions for Cytokinetics and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Cytokinetics' score of 0.86 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cytokinetics 8 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KRYS or NKTR?

In the previous week, Krystal Biotech had 14 more articles in the media than Nektar Therapeutics. MarketBeat recorded 15 mentions for Krystal Biotech and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Krystal Biotech's score of 0.86 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to NKTR or SYRE?

In the previous week, Spyre Therapeutics had 26 more articles in the media than Nektar Therapeutics. MarketBeat recorded 27 mentions for Spyre Therapeutics and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Spyre Therapeutics' score of 0.62 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spyre Therapeutics 9 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IONS or NKTR?

In the previous week, Ionis Pharmaceuticals had 17 more articles in the media than Nektar Therapeutics. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Ionis Pharmaceuticals' score of 0.19 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Nektar Therapeutics (NKTR) Competitors

$74.86 -1.62 (-2.12%)

As of 08/10/2026 04:00 PM Eastern

Compare

NKTR vs. CYTK, NUVL, KRYS, SYRE, and IONS

Should you buy Nektar Therapeutics stock or one of its competitors? Nektar Therapeutics's main competitors and comparable companies include Cytokinetics (CYTK), Nuvalent (NUVL), Krystal Biotech (KRYS), Spyre Therapeutics (SYRE), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nektar Therapeutics compare to Cytokinetics?

Nektar Therapeutics (NASDAQ:NKTR) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

75.9% of Nektar Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Nektar Therapeutics has a net margin of -284.18% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Cytokinetics	-1,321.12%	N/A	-51.01%

Nektar Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	45.80	-$164.08M	-$8.42	N/A
Cytokinetics	$88.04M	109.52	-$784.96M	-$7.22	N/A

Nektar Therapeutics presently has a consensus target price of $150.00, suggesting a potential upside of 100.37%. Cytokinetics has a consensus target price of $101.15, suggesting a potential upside of 30.53%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Cytokinetics had 24 more articles in the media than Nektar Therapeutics. MarketBeat recorded 25 mentions for Cytokinetics and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Cytokinetics' score of 0.86 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cytokinetics	8 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytokinetics beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Nuvalent presently has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Nektar Therapeutics has a consensus target price of $150.00, suggesting a potential upside of 100.37%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Nuvalent has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nuvalent's return on equity of -40.11% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Nuvalent has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Nektar Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Nektar Therapeutics	$55.23M	45.80	-$164.08M	-$8.42	N/A

In the previous week, Nektar Therapeutics had 1 more articles in the media than Nuvalent. MarketBeat recorded 1 mentions for Nektar Therapeutics and 0 mentions for Nuvalent. Nektar Therapeutics' average media sentiment score of 1.76 beat Nuvalent's score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvalent	Neutral
Nektar Therapeutics	Very Positive

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nektar Therapeutics beats Nuvalent on 8 of the 14 factors compared between the two stocks.

How does Nektar Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Krystal Biotech has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.22	$204.83M	$7.98	41.55
Nektar Therapeutics	$55.23M	45.80	-$164.08M	-$8.42	N/A

In the previous week, Krystal Biotech had 14 more articles in the media than Nektar Therapeutics. MarketBeat recorded 15 mentions for Krystal Biotech and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Krystal Biotech's score of 0.86 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Krystal Biotech presently has a consensus target price of $361.56, suggesting a potential upside of 9.04%. Nektar Therapeutics has a consensus target price of $150.00, suggesting a potential upside of 100.37%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 54.82% compared to Nektar Therapeutics' net margin of -284.18%. Krystal Biotech's return on equity of 19.34% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Summary

Krystal Biotech beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Spyre Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Spyre Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Spyre Therapeutics' return on equity of -30.74% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Nektar Therapeutics presently has a consensus price target of $150.00, indicating a potential upside of 100.37%. Spyre Therapeutics has a consensus price target of $110.15, indicating a potential upside of 4.58%. Given Nektar Therapeutics' higher probable upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	45.80	-$164.08M	-$8.42	N/A
Spyre Therapeutics	$890K	10,407.55	-$155.20M	-$1.95	N/A

In the previous week, Spyre Therapeutics had 26 more articles in the media than Nektar Therapeutics. MarketBeat recorded 27 mentions for Spyre Therapeutics and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Spyre Therapeutics' score of 0.62 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Spyre Therapeutics	9 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Summary

Spyre Therapeutics beats Nektar Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a net margin of -64.76% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Ionis Pharmaceuticals had 17 more articles in the media than Nektar Therapeutics. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.76 beat Ionis Pharmaceuticals' score of 0.19 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nektar Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	10.02	-$381.39M	-$3.46	N/A
Nektar Therapeutics	$55.23M	45.80	-$164.08M	-$8.42	N/A

Ionis Pharmaceuticals currently has a consensus price target of $94.65, indicating a potential upside of 66.23%. Nektar Therapeutics has a consensus price target of $150.00, indicating a potential upside of 100.37%. Given Nektar Therapeutics' higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Summary

Ionis Pharmaceuticals and Nektar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.58B	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-8.89	9.09	269.19	24.72
Price / Sales	45.80	1,255.18	588.76	97.80
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	16.98	17.66	11.27	6.42
Net Income	-$164.08M	-$13.25M	$3.45B	$347.03M
7 Day Performance	2.89%	3.11%	1.92%	0.69%
1 Month Performance	6.40%	-1.68%	-0.58%	-0.90%
1 Year Performance	233.16%	61.75%	75.49%	21.87%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTR Nektar Therapeutics	2.6957 of 5 stars	$74.86 -2.1%	$150.00 +100.4%	+224.6%	$2.58B	$55.23M	N/A	220	Positive News Upcoming Earnings
CYTK Cytokinetics	3.5083 of 5 stars	$78.85 +0.3%	$99.90 +26.7%	+127.2%	$9.81B	$88.04M	N/A	250	Earnings Report Analyst Downgrade Insider Trade
NUVL Nuvalent	1.8516 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
KRYS Krystal Biotech	3.854 of 5 stars	$325.78 +0.3%	$361.56 +11.0%	+139.1%	$9.60B	$389.13M	43.55	210	Earnings Report
SYRE Spyre Therapeutics	2.2402 of 5 stars	$104.35 -0.6%	$110.15 +5.6%	+594.8%	$9.18B	$890K	N/A	73	Earnings Report Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CYTK, NUVL, KRYS, SYRE, and IONS

How does Nektar Therapeutics compare to Cytokinetics?

Summary

How does Nektar Therapeutics compare to Nuvalent?

Summary

How does Nektar Therapeutics compare to Krystal Biotech?

Summary

How does Nektar Therapeutics compare to Spyre Therapeutics?

Summary

How does Nektar Therapeutics compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CYTK, NUVL, KRYS, SYRE, and IONS

How does Nektar Therapeutics compare to Cytokinetics?

Do institutionals and insiders believe in NKTR or CYTK?

Which has more volatility and risk, NKTR or CYTK?

Is NKTR or CYTK more profitable?

Which has preferable earnings and valuation, NKTR or CYTK?

Do analysts rate NKTR or CYTK?

Does the media refer more to NKTR or CYTK?

Summary

How does Nektar Therapeutics compare to Nuvalent?

Do analysts recommend NUVL or NKTR?

Is NUVL or NKTR more profitable?

Which has more volatility & risk, NUVL or NKTR?

Which has preferable earnings and valuation, NUVL or NKTR?

Does the media favor NUVL or NKTR?

Do institutionals & insiders hold more shares of NUVL or NKTR?

Summary

How does Nektar Therapeutics compare to Krystal Biotech?

Which has stronger earnings and valuation, KRYS or NKTR?

Does the media favor KRYS or NKTR?

Do analysts prefer KRYS or NKTR?

Do insiders and institutionals hold more shares of KRYS or NKTR?

Is KRYS or NKTR more profitable?

Which has more risk and volatility, KRYS or NKTR?

Summary

How does Nektar Therapeutics compare to Spyre Therapeutics?

Is NKTR or SYRE more profitable?

Do analysts recommend NKTR or SYRE?

Do insiders and institutionals have more ownership in NKTR or SYRE?

Which has stronger valuation & earnings, NKTR or SYRE?

Does the media refer more to NKTR or SYRE?

Which has more volatility and risk, NKTR or SYRE?

Summary

How does Nektar Therapeutics compare to Ionis Pharmaceuticals?

Do insiders and institutionals believe in IONS or NKTR?

Is IONS or NKTR more profitable?

Does the media favor IONS or NKTR?

Which has stronger valuation and earnings, IONS or NKTR?

Do analysts prefer IONS or NKTR?

Which has more risk and volatility, IONS or NKTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools